Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus

Bruce Hermann, Yan Li, Mukunda B. Ray, John Wo, Robert C G Martin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Hypothesis: The down-regulation of manganese superoxide dismutase (MnSOD) expression plays a role in the progression of Barrett esophagus (BE). Design: An evaluation of 92 esophageal samples, including 17 patients with normal esophagus, 22 with intestinal metaplasia, 22 with indefinite/low-grade dysplasia, 16 with high-grade dysplasia (HGD), and 15 with esophageal adenocarcinoma were evaluated for MnSOD expression. We evaluated MnSOD expression using immunohistochemistry and graded it separately on a 2-category ordinal scale in relation to the mucosa and submucosa that ranged from 0 (no staining) to 3 (strong staining). The total grading score of MnSOD immunoreactivity was the addition of mucosa and submucosa intensity, from 0 (no immunoreactivity in any of the anatomic sites) to a maximum score of 6 (strong staining reaction in both of the histoanatomic sites). Setting: Study subjects were recruited from the Barrett's Esophageal Registry at the University of Louisville, Louisville, Ky. Main Outcome Measure: Manganese superoxide dismutase expression in established groups of progressive BE. Results: Ninety-two samples were evaluated for MnSOD expression. The expression of MnSOD was found to be significantly reduced in samples with specialized intestinal metaplasia (mean score, 1.8), low-grade dysplasia (mean, 2.2), high-grade dysplasia (mean, 2.4), and esophageal adenocarcinoma (mean, 2.4) when compared with normal esophagus (mean, 3.9; P=.002). Manganese superoxide dismutase expression was similar for esophageal adenocarcinoma and high-grade dysplasia. Conclusions: Manganese superoxide dismutase expression is significantly reduced in patients with BE with highgrade dysplasia and esophageal adenocarcinoma. Manganese superoxide dismutase is related to the progression of BE and may represent one of the primary factors in oxidative stress protection. Further evaluation within genotypic expression and the role of antioxidants is needed in the effective screening and treatment of BE.

Original languageEnglish (US)
Pages (from-to)1204-1209
Number of pages6
JournalArchives of Surgery
Volume140
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Barrett Esophagus
Superoxide Dismutase
Carcinogenesis
Adenocarcinoma
Metaplasia
Staining and Labeling
Esophagus
Mucous Membrane
Registries
Oxidative Stress
Down-Regulation
Antioxidants
Immunohistochemistry
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery

Cite this

Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus. / Hermann, Bruce; Li, Yan; Ray, Mukunda B.; Wo, John; Martin, Robert C G.

In: Archives of Surgery, Vol. 140, No. 12, 12.2005, p. 1204-1209.

Research output: Contribution to journalArticle

Hermann, Bruce ; Li, Yan ; Ray, Mukunda B. ; Wo, John ; Martin, Robert C G. / Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus. In: Archives of Surgery. 2005 ; Vol. 140, No. 12. pp. 1204-1209.
@article{ef96cef3f31245eb8b2e460b0d36a4dd,
title = "Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus",
abstract = "Hypothesis: The down-regulation of manganese superoxide dismutase (MnSOD) expression plays a role in the progression of Barrett esophagus (BE). Design: An evaluation of 92 esophageal samples, including 17 patients with normal esophagus, 22 with intestinal metaplasia, 22 with indefinite/low-grade dysplasia, 16 with high-grade dysplasia (HGD), and 15 with esophageal adenocarcinoma were evaluated for MnSOD expression. We evaluated MnSOD expression using immunohistochemistry and graded it separately on a 2-category ordinal scale in relation to the mucosa and submucosa that ranged from 0 (no staining) to 3 (strong staining). The total grading score of MnSOD immunoreactivity was the addition of mucosa and submucosa intensity, from 0 (no immunoreactivity in any of the anatomic sites) to a maximum score of 6 (strong staining reaction in both of the histoanatomic sites). Setting: Study subjects were recruited from the Barrett's Esophageal Registry at the University of Louisville, Louisville, Ky. Main Outcome Measure: Manganese superoxide dismutase expression in established groups of progressive BE. Results: Ninety-two samples were evaluated for MnSOD expression. The expression of MnSOD was found to be significantly reduced in samples with specialized intestinal metaplasia (mean score, 1.8), low-grade dysplasia (mean, 2.2), high-grade dysplasia (mean, 2.4), and esophageal adenocarcinoma (mean, 2.4) when compared with normal esophagus (mean, 3.9; P=.002). Manganese superoxide dismutase expression was similar for esophageal adenocarcinoma and high-grade dysplasia. Conclusions: Manganese superoxide dismutase expression is significantly reduced in patients with BE with highgrade dysplasia and esophageal adenocarcinoma. Manganese superoxide dismutase is related to the progression of BE and may represent one of the primary factors in oxidative stress protection. Further evaluation within genotypic expression and the role of antioxidants is needed in the effective screening and treatment of BE.",
author = "Bruce Hermann and Yan Li and Ray, {Mukunda B.} and John Wo and Martin, {Robert C G}",
year = "2005",
month = "12",
doi = "10.1001/archsurg.140.12.1204",
language = "English (US)",
volume = "140",
pages = "1204--1209",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus

AU - Hermann, Bruce

AU - Li, Yan

AU - Ray, Mukunda B.

AU - Wo, John

AU - Martin, Robert C G

PY - 2005/12

Y1 - 2005/12

N2 - Hypothesis: The down-regulation of manganese superoxide dismutase (MnSOD) expression plays a role in the progression of Barrett esophagus (BE). Design: An evaluation of 92 esophageal samples, including 17 patients with normal esophagus, 22 with intestinal metaplasia, 22 with indefinite/low-grade dysplasia, 16 with high-grade dysplasia (HGD), and 15 with esophageal adenocarcinoma were evaluated for MnSOD expression. We evaluated MnSOD expression using immunohistochemistry and graded it separately on a 2-category ordinal scale in relation to the mucosa and submucosa that ranged from 0 (no staining) to 3 (strong staining). The total grading score of MnSOD immunoreactivity was the addition of mucosa and submucosa intensity, from 0 (no immunoreactivity in any of the anatomic sites) to a maximum score of 6 (strong staining reaction in both of the histoanatomic sites). Setting: Study subjects were recruited from the Barrett's Esophageal Registry at the University of Louisville, Louisville, Ky. Main Outcome Measure: Manganese superoxide dismutase expression in established groups of progressive BE. Results: Ninety-two samples were evaluated for MnSOD expression. The expression of MnSOD was found to be significantly reduced in samples with specialized intestinal metaplasia (mean score, 1.8), low-grade dysplasia (mean, 2.2), high-grade dysplasia (mean, 2.4), and esophageal adenocarcinoma (mean, 2.4) when compared with normal esophagus (mean, 3.9; P=.002). Manganese superoxide dismutase expression was similar for esophageal adenocarcinoma and high-grade dysplasia. Conclusions: Manganese superoxide dismutase expression is significantly reduced in patients with BE with highgrade dysplasia and esophageal adenocarcinoma. Manganese superoxide dismutase is related to the progression of BE and may represent one of the primary factors in oxidative stress protection. Further evaluation within genotypic expression and the role of antioxidants is needed in the effective screening and treatment of BE.

AB - Hypothesis: The down-regulation of manganese superoxide dismutase (MnSOD) expression plays a role in the progression of Barrett esophagus (BE). Design: An evaluation of 92 esophageal samples, including 17 patients with normal esophagus, 22 with intestinal metaplasia, 22 with indefinite/low-grade dysplasia, 16 with high-grade dysplasia (HGD), and 15 with esophageal adenocarcinoma were evaluated for MnSOD expression. We evaluated MnSOD expression using immunohistochemistry and graded it separately on a 2-category ordinal scale in relation to the mucosa and submucosa that ranged from 0 (no staining) to 3 (strong staining). The total grading score of MnSOD immunoreactivity was the addition of mucosa and submucosa intensity, from 0 (no immunoreactivity in any of the anatomic sites) to a maximum score of 6 (strong staining reaction in both of the histoanatomic sites). Setting: Study subjects were recruited from the Barrett's Esophageal Registry at the University of Louisville, Louisville, Ky. Main Outcome Measure: Manganese superoxide dismutase expression in established groups of progressive BE. Results: Ninety-two samples were evaluated for MnSOD expression. The expression of MnSOD was found to be significantly reduced in samples with specialized intestinal metaplasia (mean score, 1.8), low-grade dysplasia (mean, 2.2), high-grade dysplasia (mean, 2.4), and esophageal adenocarcinoma (mean, 2.4) when compared with normal esophagus (mean, 3.9; P=.002). Manganese superoxide dismutase expression was similar for esophageal adenocarcinoma and high-grade dysplasia. Conclusions: Manganese superoxide dismutase expression is significantly reduced in patients with BE with highgrade dysplasia and esophageal adenocarcinoma. Manganese superoxide dismutase is related to the progression of BE and may represent one of the primary factors in oxidative stress protection. Further evaluation within genotypic expression and the role of antioxidants is needed in the effective screening and treatment of BE.

UR - http://www.scopus.com/inward/record.url?scp=29144518721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144518721&partnerID=8YFLogxK

U2 - 10.1001/archsurg.140.12.1204

DO - 10.1001/archsurg.140.12.1204

M3 - Article

C2 - 16365243

AN - SCOPUS:29144518721

VL - 140

SP - 1204

EP - 1209

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 12

ER -